Healthcare industry

The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.

Vaccine development - 02/06/2020

CureVac as a pioneer of mRNA technology – what is behind the novel COVID-19 vaccine?

All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

Material research - 25/05/2020

Reaching up into weightlessness – a start-up that enables commercial research experiments in space

Yuri, a start-up company founded in 2019 in the Lake Constance area, is aiming high. The company’s mission is to enable microgravity research into the development of materials, new medicines and vaccines, including research opportunities on the International Space Station (ISS). Yuri’s tailor-made solutions are faster and more affordable than previous space research missions.

Prime Vector Technologies GmbH - 09/04/2020

A modular brick system for developing a COVID-19 vaccine

Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

Novel coronavirus outbreak - a status report on recent developments - 04/03/2020

Waiting for a SARS-CoV-2 vaccine

Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, today announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional antibodies against diseases with poor treatment options. Further details of the financing round were not disclosed.

Company profile - 19/12/2018

With DiHeSys into integrated digital healthcare

The founders and partners of DiHeSys have big ambitions: "We have to build a complete ecosystem around the patient," says Dr. Markus Dachtler, managing director of DiHeSys. The company develops products and services for an industry in transition, provides answers to trends such as personalized medicine, 2D- and 3D-printing technologies and platform technologies. The company’s motto: no isolated solutions, but a comprehensive range of…

CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.

Article - 18/10/2017

Testing a new antibody therapy for treating blood cancer

The fight against acute myeloid leukaemia is a long one. Cancer cells that cause the disease to recur may remain despite initially successful destruction of the tumour with chemotherapy drugs. Now researchers from Tübingen have identified an antibody that could potentially prevent cancer recurrence.

Article - 22/08/2016

Ad-O-Lytics – a new biotech start-up from Ulm

A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…

Article - 20/06/2016

New diagnostic tool for greater health safety when dealing with multidrug-resistant pathogens

Infections with antibiotic-resistant bacteria and diseases such as breast or colon cancer are among the major causes of death worldwide. Early diagnosis is therefore key for the identification of people affected and for providing immediate therapy. The R&D service provider Hahn-Schickard and its partners are currently working on the development of a rapid and simple diagnostic system that can detect life-threatening infections and cancer at…

Press release - 03/11/2015

CureVac raises $110 Million in a private placement

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).

Press release - 29/04/2015

cytena received EUR 1.1 million of seed capital from HTGF and a private investor

cytena GmbH, headquartered in Freiburg, has developed a device called cy-Clone to separate single cells. A consortium made up of a private investor and High-Tech Gründerfonds (HTGF), will provide EUR 1.1 million of seed capital. cytena GmbH will use this capital injection primarily to launch its product and to expand its marketing and distribution activities.

Article - 11/08/2014

PRONTO develops microsystems for and with companies

Since 2010, PRONTO, a project run by the MicroTEC Südwest cluster, has been focusing on the production of innovative microsystems for application in the medical and other sectors. PRONTO provides microsystems development support up to small-scale production. Customers who are seeking to implement their ideas into concrete microsystems solutions can count on the expertise and infrastructure of four institutes.

Press release - 16/10/2013

BIOTECHNICA 2013 - Baden-Württemberg is a top life sciences spot.

The BIOTECHNICA trade show rolled out the red carpet for its exhibitors. Over 10,000 visitors walked over the carpet to inspect the exhibits that were on display at the Baden-Württemberg booth. The impressive exhibits of the companies showed that Baden-Württemberg has many highly innovative SMEs in the life sciences field.

Article - 04/05/2013

Ionera – measuring tiny ion currents

The identification and characterisation of individual DNA and protein molecules is gaining in importance. A method developed by Dr. Gerhard Baaken and Prof. Dr. Jan C. Behrends at the University of Freiburg has the potential to be used by scientists to analyse a large number of single molecules automatically using nanopores. The MECA (microelectrode cavity array) technology can be adapted to a broad range of different applications.

Article - 17/12/2012

Medicyte GmbH – gold standard for human cells

Medicyte GmbH is a life sciences company located in the city of Heidelberg. It focuses primarily on the production of quasi-primary human cells of the highest quality and in virtually unlimited quantity. MediCyte’s goal is to establish its proprietary cell proliferation technologies as gold standard for the use of human cells and cell products in research, development and cell therapy.

Article - 17/09/2012

Thomas Paulöhrl: spatially and temporally controlled light-induced reactions

Thomas Paulöhrl, polymer chemist from the Karlsruhe Institute of Technology (KIT), was awarded the 2012 Lanxess Talent Award for his achievements in further developing light-induced click strategies that can now be used for generating various surface structures and three-dimensional frameworks. His Ph.D. thesis not only provides the basis for new ways to efficiently modify material, it also opens up new research opportunities in medical drug…

Article - 17/09/2012

Alexander Wittemann: polymeric nanostructures as carriers of biomolecules

Vesicles form naturally in cells and can do many things including transporting pharmaceutically active substances to tumours. However natural vesicles only have a short lifespan which can lead to the premature release of the drug enclosed within them. Alexander Wittemann a chemist at Konstanz University has successfully developed artificial biocompatible polymer vesicles with a much longer lifespan.

Dossier - 24/05/2012

Biochips: microsystems technology for the life sciences

Nanoscale robots and intelligent measurement systems in arteries, fingernail-sized DNA chips that can be used to analyze thousands of genes in tiny samples, intelligent DNA microsensors – the trend in the life sciences is moving towards miniaturization in all areas including electronics, sensor systems and the handling of liquids. Over the last few years, a research area with growing potential has developed at the interface of physics, the…

Press release - 23/05/2012

GlaxoSmithKline to fully acquire Cellzome for 99 million U.S. dollar

GlaxoSmithKline plc (GSK) announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK’s R&D organisation.

Press release - 16/05/2012

OGpharma in China

OGpharma (CEO: Dr. Wanzhou ZHAO) is a Contract Research Company (CRO) located in Nanjing’s Gulou Science Park. The company offers two services: a) contract research, and b) consulting service for international cooperation.

Article - 25/07/2011

CellGenix GmbH – Cell therapy and all that is needed

CellGenix was spun out of the Freiburg University Medical Centre around 17 years ago with the aim of cultivating and commercialising therapeutic cell material in compliance with high safety and quality standards. The Freiburg-based company has since become a leading manufacturer and supplier of cartilage cells and umbilical cord stem cells.

Press release - 27/06/2011

NMI TT GmbH – creating value from research

NMI TT GmbH is a subsidiary of the NMI Natural and Medical Sciences Institute in Reutlingen with which it works closely. Developments by the renowned NMI are commercialised by NMI TT GmbH and the profit flows back into the NMI’s research activities – thus leading to a value creation cycle that benefits research and development as well as the economy.

Press release - 23/05/2011

Systems biology in Baden-Württemberg

The emerging interdisciplinary field of systems biology is pursuing a completely new approach namely the description of the dynamic interplay of all the components of a biological system using mathematical models with the aim of obtaining a holistic view of the system under consideration. This new approach is expected to lead to new approaches for the treatment of diseases and for the industrial production of enzymes. With its three systems…